Cerity Partners LLC Acquires 31,112 Shares of Abbott Laboratories $ABT

Cerity Partners LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,538,380 shares of the healthcare product maker’s stock after buying an additional 31,112 shares during the quarter. Cerity Partners LLC owned approximately 0.09% of Abbott Laboratories worth $209,227,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. AlphaCore Capital LLC bought a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $584,000. Zions Bancorporation National Association UT purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $561,000. Donoghue Forlines LLC bought a new position in Abbott Laboratories in the 1st quarter worth approximately $2,293,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in Abbott Laboratories by 200.6% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 460,012 shares of the healthcare product maker’s stock valued at $61,021,000 after buying an additional 306,991 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.3%

ABT opened at $125.01 on Friday. The business’s fifty day simple moving average is $128.53 and its 200 day simple moving average is $130.80. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market cap of $217.38 billion, a PE ratio of 15.67, a P/E/G ratio of 2.28 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter last year, the company earned $1.21 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.9%. The ex-dividend date was Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. Mizuho raised their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. BTIG Research reaffirmed a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a report on Thursday, November 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Abbott Laboratories in a research report on Wednesday, October 8th. Wells Fargo & Company upped their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Finally, Raymond James Financial raised their price target on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.